Clinical Investigation of Efficacy of Third-line and Beyond Pemetrexed Treatment in Advanced Non-squamous Non-small Cell Lung Cancer
Background and objective Pemetrexed in combination with platinum or a single-agent has been approved for the first- and second-line treatment of non-small cell lung cancer (NSCLC). However, the role of pemetrexed therapy in the third-line and beyond treatment of NSCLC has yet to be generally accepte...
Main Authors: | Fei YU, Xiaoqing LIU, Xiaoyan LI, Jianjie LI, Wanfeng GUO, Haifeng QIN, Hongjun GAO |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2012-02-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.10 |
Similar Items
-
Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients
with Advanced Non-small Cell Lung Cancer
by: Junling LI, et al.
Published: (2012-03-01) -
A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy
for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01) -
Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
by: Biao WU, et al.
Published: (2010-08-01) -
Clinical observation of Alimta monotherapy in treatment of advanced non-small cell lung cancer
by: Haiyan WANG, et al.
Published: (2008-06-01) -
Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
by: Sun Young JUNG, et al.
Published: (2011-01-01)